Sign in →

Test Code LAB13028 Preeclampsia sFlt-1/PIGF (Soluble fms-Like Tyrosine Kinase 1/ Placental Growth Factor) Ratio, Serum


Ordering Guidance


The test is indicated for use in pregnant women, with singleton pregnancies (gestational age 23 to 34+6/7 weeks) hospitalized for hypertensive disorders of pregnancy (preeclampsia, chronic hypertension with or without superimposed preeclampsia or gestational hypertension), within 2 weeks of presentation.



Specimen Required


Patient Preparation: For 24 hours before specimen collection, the patient should not receive intravenous heparin.

Supplies: Sarstedt Aliquot Tube, 5 mL (T914)

Collection Container/Tube:

Preferred: Serum gel

Acceptable: Red top

Submission Container/Tube: Plastic vial

Specimen Volume: 0.5 mL serum

Collection Instructions: Centrifuge and aliquot serum into a plastic vial.


Secondary ID

621166

Useful For

Aiding in risk assessment of patients with clinical signs and symptoms consistent with development of preeclampsia with severe features

 

This test is not intended for making a diagnosis of preeclampsia or preeclampsia with severe features.

 

This test is not a stand-alone test for monitoring of hypertensive disorders of pregnancy or for changing treatment, including medication.

Method Name

Immunofluorescent Assay (IFA)

Reporting Name

Preeclampsia sFlt-1/PlGF Ratio, S

Specimen Type

Serum

Specimen Minimum Volume

Serum: 0.3 mL

Specimen Stability Information

Specimen Type Temperature Time
Serum Frozen (preferred) 180 days
  Refrigerated  24 hours

Reject Due To

Gross hemolysis OK
Gross lipemia OK
Gross icterus Reject

Reference Values

<40

Cautions

The B·R·A·H·M·S PIGF (placental growth factor) plus KRYPTOR assay must be run in conjunction with the B·R·A·H·M·S sFlt-1 (soluble fms-like tyrosine kinase 1) KRYPTOR assay and the same patient sample must be used to run both assays. Use of another manufacturer's assays may result in significantly different results.

 

The sFlt-1/PlGF ratio should not be used for a woman with a multiple pregnancy because the safety and effectiveness of the assay has not been established in women pregnant with multiple fetuses (twins, triplets, etc).

 

The sFlt-1/PlGF ratio should not be used for a woman receiving intravenous heparin for 24 hours prior to testing because the safety and effectiveness of the assay has not been established in such cases.

 

The sFlt-1/PlGF ratio should not be used for women receiving exogenous PlGF-2 or PlGF-3 for therapeutic use at concentrations higher than 100 pg/mL because the safety and effectiveness of the assay has not been established in such cases. However, in samples with equal concentrations of PIGF-1 and PIGF-2, the measurement of PIGF-1 was relatively unaffected.

 

The results of the test are not intended to inform the healthcare provider whether to change treatment, including medication or hospitalization.

 

In rare cases, some individuals can develop antibodies to mouse or other animal antibodies (often referred to as human anti-mouse antibodies [HAMA] or heterophile antibodies), which may cause interference in some immunoassays. Caution should be used in interpretation of results, and the laboratory should be alerted if the result does not correlate with the clinical presentation.

Day(s) Performed

Monday through Saturday

Report Available

1 to 3 days

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test has been cleared, approved, or is exempt by the US Food and Drug Administration and is used per manufacturer's instructions. Performance characteristics were verified by Mayo Clinic in a manner consistent with CLIA requirements.

CPT Code Information

0482U

LOINC Code Information

Test ID Test Order Name Order LOINC Value
PERA Preeclampsia sFlt-1/PlGF Ratio, S 74757-6

 

Result ID Test Result Name Result LOINC Value
PERAT sFlt-1/PlGF Ratio 74757-6

NY State Approved

Yes